Braftovi (Encorafenib)

Braftovi (encorafenib) is a kinase inhibitor used for the management of certain types of cancer. It is a kinase inhibitor. It works in combination with other medicines for better results. Braftovi is used with binimetinib to treat adults with unresectable or metastatic melanoma that has a BRAF V600E or V600K mutation. It is also used with cetuximab to treat adults with metastatic colorectal cancer (CRC) with a BRAF V600E mutation. Additionally, Braftovi is combined with binimetinib to treat adults with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation. 

Limitations of Use: Do not use this therapeutic drug for the treatment of patients with wild-type BRAF melanoma, wild-type BRAF CRC, or wild-type BRAF NSCLC.

Recommended Dosage: Confirm the presence of a BRAF V600E or V600K mutation in tumor specimens before starting treatment with Braftovi. 

• Melanoma and Non-Small Cell Lung Cancer (NSCLC): The recommended dosage is 450 mg (six 75 mg capsules) orally once daily together with binimetinib until there is evidence of disease progression or unacceptable toxicity.
• Colorectal Cancer (CRC): The recommended dosage is 300 mg (four 75 mg capsules) orally once daily together with cetuximab until there is evidence of disease progression or unacceptable toxicity. 

Braftovi capsules may be taken with or without food. Do not take a missed dose within 12 hours of the next dose of Braftovi. Do not take any additional dose if vomiting occurs after the administration of this medication but continue with the very next scheduled dose.

• Treatment with Braftovi 75 mg capsules may increase the probability of developing new primary cancers, such as cutaneous squamous cell carcinoma or basal cell carcinoma (BCC). Regular skin examinations are recommended before, during, and after treatment to recognize and manage malignancies appropriately.
• This therapy can increase the growth of tumors in patients with BRAF wild-type tumors. Avoid its use in these situations and confirm BRAF V600E or V600K mutation status through approved diagnostic tests before starting treatment.
• Encorafenib treatment may reduce heart function, which may cause cardiomyopathy. Monitor cardiac function before and during treatment, mainly in patients with heart disease. Let your doctor know if you experience fatigue, shortness of breath, or swelling in your legs.
• Liver problems, including increased liver enzyme levels, can arise with the use of this medication. Regularly monitor liver function tests and let your doctor know if you notice symptoms such as yellowing of the skin or eyes, dark urine, or severe abdominal pain.
• Serious bleeding events, including gastrointestinal and intracranial hemorrhages, have been reported. Patients should be monitored for signs of bleeding, such as unusual bruising or black stools. Notify your doctor immediately if bleeding occurs.
• Eye inflammation, including uveitis, can occur during treatment with Braftovi. Symptoms include eye pain, redness, or vision changes. Regular eye examinations are recommended, and report any eye problems to your healthcare provider promptly.
• Treatment with Braftovi 75 mg oral capsules can harm an unborn baby. Women of childbearing age should use effective contraception during treatment and for at least 2 weeks after the last dose. Men with partners who may become pregnant should also use contraception.
• Patients receiving treatment with this therapeutic drug should avoid breastfeeding during and for at least 2 weeks after the last dose. It is unknown if the drug passes into breast milk, but it could harm a nursing baby.

What documents are required to import BRAFTOVI to India?

Indian Pharma Network is able to source the BRAFTOVI (Cancer Treatment Medicines) from across the globe, and has the ability to supply. Indian Pharma Network offers its customers worldwide access to the best available treatment.

Indian Pharma Network is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Braftovi®?

Encorafenib is Generic Name for the trade name drug Braftovi®.

What is the Manufacturer Name of Braftovi®?

Braftovi® is manufactured by Pfizer Inc.

Is Braftovi® approved by the FDA?

Yes, Braftovi® is approved by the FDA. Date of first/initial approval: June 27, 2018.

Where can I get Braftovi® at the best price in India?

To get the best Braftovi capsule price in India, contact Indian Pharma Network (WHO-GDP & ISO 9001:2008 authorized Company). A medical prescription is required while buying Braftovi®.

What is the dosage and form of Braftovi® supplied?

Braftovi® is supplied as Capsules: 75 mg for oral administration. 

What are the most common side effects of Braftovi® in combination with binimetinib? 

The most common side effects for Braftovi® in combination with binimetinib, are fatigue, abdominal pain, nausea, vomiting, and arthralgia. 

What are the most common side effects of Braftovi® in combination with cetuximab? 

The most common side effects for Braftovi®in combination with cetuximab, are diarrhea, dermatitis acneiform, fatigue, nausea, abdominal pain, decreased appetite, rash, and arthralgia. 

How much does Braftovi® cost in India?

Prices of Braftovi may vary over time because of market dynamics and regulatory changes. To get the most up-to-date details on Braftovi 75 mg cost in India, please Call/WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

Can Braftovi® be available in SAARC countries? 

Apart from Gulf countries, Braftovi 75 mg can be available in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the legal supply of Braftovi capsules in these countries. We help ensure legal access to this therapeutic drug through our reliable channels.

Is it safe to buy Braftovi 75 mg capsules online from India? 

Yes, one can buy Braftovi 75 mg online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can facilitate the supply of Braftovi 75 mg capsules through legal channels. 

What are the storage conditions of Braftovi®?

Store capsules at 20-25°C (68-77°F); excursions permitted between 15°C and 30°C (59°F and 86°F). Do not use it if the safety seal under the cap is broken/missing. Dispense in the original bottle. Protect from moisture. Keep the container tightly closed.